|40.40||-2.69||-6.24%||Vol 1.13M||1Y Perf -60.41%|
|Jun 28th, 2022 16:00 DELAYED|
|- -||0.10 0.25%|
|Target Price||95.38||Analyst Rating||Strong Buy 1.44|
|Potential %||136.09||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★ 45.66|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||11.40||Earnings Rating||—|
|Market Cap||2.84B||Earnings Date||9th Aug 2022|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||9th Aug 2022|
|Estimated EPS Next Report||-1.08|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.57M|
|Avg. Monthly Volume||1.43M|
|Avg. Quarterly Volume||1.29M|
Beam Therapeutics Inc. (NASDAQ: BEAM) stock closed at 43.09 per share at the end of the most recent trading day (a 1.36% change compared to the prior day closing price) with a volume of 1.05M shares and market capitalization of 2.84B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 166 people. Beam Therapeutics Inc. CEO is John Evans.
The one-year performance of Beam Therapeutics Inc. stock is -60.41%, while year-to-date (YTD) performance is -45.93%. BEAM stock has a five-year performance of %. Its 52-week range is between 27.77 and 138.5219, which gives BEAM stock a 52-week price range ratio of 11.40%
Beam Therapeutics Inc. currently has a PE ratio of -11.90, a price-to-book (PB) ratio of 3.60, a price-to-sale (PS) ratio of 50.24, a price to cashflow ratio of 14.80, a PEG ratio of 2.32, a ROA of -22.20%, a ROC of -30.98% and a ROE of -38.08%. The company’s profit margin is -%, its EBITDA margin is -429.70%, and its revenue ttm is $60.27 Million , which makes it $0.86 revenue per share.
Of the last four earnings reports from Beam Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.08 for the next earnings report. Beam Therapeutics Inc.’s next earnings report date is 09th Aug 2022.
The consensus rating of Wall Street analysts for Beam Therapeutics Inc. is Strong Buy (1.44), with a target price of $95.38, which is +136.09% compared to the current price. The earnings rating for Beam Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Beam Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Beam Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.09, ATR14 : 3.89, CCI20 : 144.06, Chaikin Money Flow : 0.30, MACD : 0.92, Money Flow Index : 69.78, ROC : 7.24, RSI : 61.88, STOCH (14,3) : 93.89, STOCH RSI : 1.00, UO : 71.01, Williams %R : -6.11), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Beam Therapeutics Inc. in the last 12-months were:
Wed, 11 May 2022 01:57 GMT Beam Therapeutics (BEAM) Gets a Hold Rating from RBC Capital- TipRanks. All rights reserved.
Mon, 10 Jan 2022 16:30 GMT Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM) and Karyopharm Therapeutics (KPTI)- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.